Cruel Summer: High-Profile Trial Failures Dominate R&D News Flow
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
As the summer of 2012 wears on, an outpouring of negative clinical trial news for high-profile new drug candidates has made the season more a time of doldrums than of fun in the sun for big pharma.
You may also be interested in...
Lilly Pulls The Plug On Next-Gen Antipsychotic
With one Phase III trial failed and a second halted for futility, Eli Lilly calls it quits on pomaglumetad methionil, a compound the pharma had hoped would succeed blockbuster antipsychotic Zyprexa, marking the end of the road for a pioneering compound in the effort to drug metabotropic glutamate receptors (mGluRs), a promising class for CNS therapies.
Beyond Bapi: Alzheimer’s Pipeline Runs Deep
With the failure of the second of four Janssen-led Phase III trials testing bapineuzumab, partners Janssen and Pfizer have elected to discontinue the bapineuzumab I.V. clinical development program. Nonetheless, the anti-amyloid-beta approach is still alive, as the field turns to early, pre-symptomatic intervention.
Does Bristol Nuc’s Possible Cardiac Toxicity Portend A Class Effect?
Bristol-Myers Squibb has halted study of its Phase II nucleoside polymerase inhibitor for hepatitis C due to one trial patient suffering heart failure. It remains unclear if that event is related to the study drug, but do repeated toxicity issues with “nucs” indicate a class effect?